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PURPOSE. To evaluate the angiogenic properties of corneal derived mesenchymal stromal cells
(Co-MSC).
METHODS. Co-MSCs were extracted from human cadaver, and wild-type (C57BL/6J) and
SERPINF1/ mice corneas. The MSC secretome was collected in a serum-free medium.
Human umbilical vein endothelial cell (HUVEC) tube formation and fibrin gel bead assay
(FIBA) sprout formation were used to assess the angiogenic properties of Co-MSC secretome.
Complete corneal epithelial debridement was used to induce corneal neovascularization in
wild-type mice. Co-MSCs embedded in fibrin gel was applied over the debrided cornea to
evaluate the angiogenic effects of Co-MSCs in vivo. Immunoprecipitation was used to remove
soluble fms-like tyrosine kinase-1 (sFLT-1) and pigment epithelium-derived factor (PEDF,
SERPINF1 gene) from the Co-MSC secretome.
RESULTS. Co-MSC secretome significantly inhibited HUVECs tube and sprout formation. Co-
MSCs from different donors consistently contained high levels of antiangiogenic factors
including sFLT-1 and PEDF; and low levels of the angiogenic factor VEGF-A. In vivo,
application of Co-MSCs to mouse corneas after injury prevented the development of corneal
neovascularization. Removing PEDF or sFLT-1 from the secretome significantly diminished the
antiangiogenic effects of Co-MSCs. Co-MSCs isolated from SERPINF1/mice had significantly
reduced antiangiogenic effects compared to SERPINF1þ/þ (wild-type) Co-MSCs.
CONCLUSIONS. These results illustrate the direct antiangiogenic properties of Co-MSCs, the
importance of sFLT-1 and PEDF, and their potential clinical application for preventing
pathologic corneal neovascularization.
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Mesenchymal stromal cells (MSCs) play an important role intissue repair and maintenance and provide an attractive
candidate for cell-based therapies.1–3 Bone marrow MSCs, and
to a lesser extent adipose and umbilical cord derived MSCs,
have been investigated for a wide range of human diseases
based on their anti-inflammatory, antifibrotic and other tissue
repair properties.4–9 We hypothesized that corneal tissue MSCs
may be particularly suitable for therapeutic applications in the
cornea.
Absence of blood vessels in the cornea is integral to its
transparency and its immune-privileged status.10 Corneal
avascularity is largely maintained through the local production
of antiangiogenic factors, including VEGF receptor 3; soluble
fms-like tyrosine kinase-1 (sFLT-1; also known as soluble VEGF
receptor 1); and pigment epithelium derived factor (PEDF).11,12
Corneal neovascularization is often the final consequence of
severe corneal infections or inflammation, which alter the
balance in favor of angiogenic factors. Importantly, neovascu-
larization makes the cornea less amenable to treatments via
cadaveric corneal transplantation given the loss of the corneal
immune privilege.13
In this current study, we test the hypothesis that cornea-
derived MSCs have intrinsic antiangiogenic properties and
further investigate the mechanism for their direct antiangio-
genic effects.
METHODS
Mice
All experiments in mice were conducted in compliance with
the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. The protocols were approved by the Animal
Care & Use Committee of the University of Illinois at Chicago
(UIC). SERPINF1/ on C57BL/6J background mice were
provided by Paul J. Grippo, PhD, (UIC). C57BL/6J mice were
used as wild-type.
MSC Culture
Human and mice Co-MSCs were isolated and expanded as
described before.1,2,14,15 Briefly, the corneoscleral button from
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healthy cadaver eyes (provided by Eversight Eye Bank, Ann
Arbor, MI, USA) or freshly enucleated mouse eyes were washed
five times with PBS containing 2X Antibiotic-Antimycotic and
2X penicillin- streptomycin (both from Thermo Fisher Scien-
tific, Waltham, MA, USA). After removing the central button
with a trephine, the limbus was cut into three segments that
were placed in 2.4 IU of protease (Dispase II; Thermo Fisher
Scientific) for 1 hour at 378C. Intact epithelial sheets were
removed from stroma. The limbal segments were cut into small
pieces and incubated in collagenase Type I (0.5 mg/mL)
(Sigma-Aldrich Corp., St. Louis, MO, USA) in DMEM/F12 media
(Thermo Fisher Scientific) overnight at 378C or used directly
for explant culture. The digests were filtered through a 70-lm
nylon strainer to obtain a single-cell suspension. They were
seeded onto 1% gelatin (Sigma-Aldrich Corp.)–coated wells of a
6-well tissue culture plate in alpha MEM media supplemented
with 10% fetal bovine serum, 1X L-Glutamine, and 1X NEAA
(all from Corning, Manassas, VA, USA). Culture media were
changed every other day, and cells were subcultured by brief
digestion with reagent (TrypLE Express; Thermo Fisher
Scientific) when 80% confluent.
Cell Transplantation
Total limbal stem cell deficiency was induced by total corneal
epithelial debridement as described before.16 A 6-0 nylon
suture was prepassed through the lids (in preparation for
closing the lids afterward). Subsequently, 0.2 lL thrombin
(Ethicon, Somerville, NJ, USA) was placed over the debrided
cornea. A total of 5000 cells, resuspended in 3 lL fibrinogen
(Ethicon), were transferred over the cornea. After the gel
formed, the suture was tightened. Erythromycin ophthalmic
ointment was applied. The suture was removed after 3 days.
MSC Secretome
Upon reaching 100% confluency in a T175 flask, the MSCs were
washed with 30 mL prewarmed PBS 3 times. The media was
then changed to phenol red free alpha MEM media supple-
mented with 1X L-Glutamine, and 1X NEAA. The conditioned
media was collected after 48 hours. The cells were trypsinzed
and counted at the same time. The conditioned media was
centrifuged with 500 G speed for 15 minutes to remove any
cells or debris. The supernatant was transferred to a new tube
and was used for experiments or kept at 48C for up to a week.
Tube Formation Assay
Human umbilical vein endothelial cells (HUVEC; Thermo
Fisher Scientific) were cultivated in specialty media (Medium
200; Thermo Fisher Scientific) fortified with low serum growth
supplement (LSGS). At passage 4, the cells were detached and
resuspended in medium (Thermo Fisher Scientific) þ 10%
LSGS, which was used as the base media. The 96-well plate
were filled with 75 lL gelatinous protein mixture (Matrigel;
Thermo Fisher Scientific) and allowed to solidify at 378C, after
which HUVECs (2 3 104 cells/75 lL) were gently seeded on
top of the gel. Subsequently, 75 lL of secretome, complete
media, or specialty media (Thermo Fisher Scientific) was added
as the testing condition, positive, and negative controls,
respectively. After 6 hours, network structures were analyzed
and photographed at 34 magnification (Leica Microsystems,
Wetzlar, Germany). Total tubule length per image was
calculated using angiogenesis analyzer plugin of ImageJ
(http://imagej.nih.gov/ij/; provided in the public domain by
the National Institutes of Health [NIH], Bethesda, MD, USA).
Fibrin Induced Bead Assay
Fibrin induced bead assay (FIBA) was performed as described
previously.17 Briefly, HUVECs (passage 3 to 5) were stained
with red dye (Cat. No. C34565, CellTracker Deep Red Dye
Thermo Fisher). A total of 2500 presterilized microcarrier
beads (Cytodex 3; Sigma-Aldrich Corp., Cat. No. C3275) were
mixed with 1 3 106 HUVECs in specialty medium (Thermo
Fisher Scientific) þ LSGS (complete media) and incubated
overnight. A total of 250 precoated beads in 500 lL of 2 mg/mL
fibrinogen (Cat. No. F8630; Sigma-Aldrich Corp.)þ 0.15 units/
mL aprotinin (Cat. No. A6106; Sigma-Aldrich Corp.) was
seeded per well of a 24-well plate. The bead-fibrinogen
solution was coagulated by adding 0.625 unit/mL thrombin
(Cat. No. T7513; Sigma-Aldrich Corp.). Subsequently, 500 lL of
specialty medium (Thermo Fisher Scientific) þ 10% LSGS was
added to the surface of the clotted fibrin gel dropwise,
followed by 500 lL of secretome, complete media, or specialty
medium (Thermo Fisher Scientific) as testing condition,
positive, and negative controls, respectively. After 3 days,
images were captured and analyzed using ImageJ software.
Immunostaining
Corneal whole mount immunostaining was done as described
before.18 Briefly, after enucleation of the eye, the cornea was
dissected using a spring scissor. It was then fixed with 4%
paraformaldehyde at 48C overnight. After washing with PBS, it
was incubated with 20 lg/mL serine protease (Proteinase-K;
Sigma-Aldrich Corp.) for 5 minutes at room temperature
followed by 100% methanol for another 30 minutes. It was
then incubated with 10% serum and 2% bovine serum albumin
(BSA) at 48C overnight. Purified anti-mouse CD31 (Cat. No.
102401; BioLegend) was used as primary antibody and
Rhodamine-conjugated donkey anti-rat IgG (Cat. No. 712–02–
153; Jackson ImmunoResearch, West Grove, PA, USA) as
TABLE. Antibodies Used for Flow Cytometry
Antibody Species Fluorochrome Clone Catalog Number Manufacturer
CD90 Human PE-Cy7 5E10 328124 BioLegend
CD39 Human FITC A1 328206 BioLegend
CD73 Human BV510 AD2 563198 BD Pharmingen
CD106 Mouse FITC MVCAM.A 105705 BioLegend
CD45 Mouse FITC 30-F11 103107 BioLegend
Sca1 Mouse FITC D7 108105 BioLegend
CD11b Mouse FITC M1/70 101205 BioLegend
CD44 Mouse FITC IM7 103005 BioLegend
CD105 Mouse PE MJ7/18 120407 BioLegend
CD73 Mouse PE TY/11.8 127205 BioLegend
CD29 Mouse PE HMO¨1-1 102207 BioLegend
Corneal MSCs are Directly Antiangiogenic IOVS j October 2017 j Vol. 58 j No. 12 j 5508
FIGURE 2. Corneal MSCs (Co-MSCs) are directly antiangiogenic in vitro. (A) Co-MSC secretome significantly inhibited mean sprout count per bead
and mean sprout length in a fibrin-induced bead assay (n ¼ 5). *P < 0.001. Scale bars: 200 lm. (B) Co-MSC secretome (6.8 6 1.0 mm/field)
significantly reduced tubule formation in a HUVEC assay (n¼ 5). *P < 0.003. The values shown are mean 6 SD (error bars). S, secretome.
FIGURE 1. Human and mouse corneal stromal cells demonstrate mesenchymal stromal cells (MSC) features. (A) Bright-field image of passage-4
human corneal MSCs. (B) Flow cytometry analysis demonstrated a homogenous MSC population. More than 95% of the cells were positive for cell
surface markers CD73, CD90, CD105, and negative for CD19, CD45, HLA-DR, CD11b, and CD34 (n ¼ 10). (C) Differentiation into the three
mesenchymal lineages: I: Osteogenesis: calcium deposition stained with Alizarin Red; II: Adipogenesis: lipid formation stained with LipidTOX; III:
Chondrogenesis: Glycosaminoglycans stained with Alcian Blue. (D) Bright-field microscopy image of passage-4 mouse corneal MSCs. (E) Flow
cytometry analysis demonstrated a homogenous MSC population. More than 95% of the cells are positive for cell surface markers CD29, Sca-1,
CD105, CD44 and CD106 and negative for CD11b, and CD45. (F) Differentiation into the three mesenchymal lineages: I: Calcium deposition stained
with Alizarin Red; II: Lipid formation stained with LipidTOX; III: Glycosaminoglycans stained with Alcian Blue.
Corneal MSCs are Directly Antiangiogenic IOVS j October 2017 j Vol. 58 j No. 12 j 5509
secondary antibody. The slides were visualized and photo-
graphed using a commercial microscope (Zeiss LSM 710; Carl
Zeiss Meditec, Jena, Germany). To make the quantification
more objective, we used VesselJ19 to quantify the ratio of
vascularized area to total corneal area.
Human Proteome Array Analysis
The expression levels of proteins known for their roles in
angiogenesis were analyzed using an antibody array (Proteome
Profiler Human Angiogenesis Array Kit; R&D System, Minne-
apolis, MN, USA) according to the manufacturer’s instruction.
Enzyme-Linked Immunosorbent Assay
Human PEDF (Cat. No. DY1177-05); sFLT-1 (Cat. No.
DVR100B); and VEGF-A (Cat. No. DVE00) proteins were
detected with commercially available ELISA kits (all from
R&D Systems) according to the manufacturer’s protocol. The
obtained values were normalized to total cell numbers.
Immunoprecipitation (IP)
Co-MSC secretome was incubated with 25 lg/mL anti-PEDF
(Cat. No. AF1177); anti-sFlt1 (Cat. No. AF321); or normal Goat
IgG (Cat. No. AB 108-C) antibody (all from R&D) at 48C
overnight. After washing of the beads with IP buffer (Cat. No. I-
5779; Sigma-Aldrich Corp.), samples were incubated with 30 ll
of protein G beads (Sigma-Aldrich Corp. Cat. No. P-3296) at 48
C for 2 hours. The samples were centrifuged at 12000 g for 30
seconds. The supernatant was checked for the efficiency of IP.
It was then used for the experiments.
siRNA Transfection
After reaching 70% to 80% of confluency, Co-MSCs were
transfected with 50 nM SERPINF1 siRNA (Cat. No. sc-40947;
Santa Cruz Biotechnology, Dallas, TX, USA) or scrambled siRNA
(Cat. No. D-001205; Dharmacon, Lafayette, CO, USA) in
TransIT-TKO siRNA transfection reagent (Cat. No. MIR2150;
Mirus Bio LLC, Madison, WI, USA). The transfection efficiency
was tested with ELISA on the secretome.
Flow Cytometry
The cells were detached as described above. They were
incubated with Fc block (Cat. No. 564220 for human; BD
Pharmingen, San Jose, CA, USA, and TruStain fcX [anti-mouse
CD16/32], Cat. No. 101319 for mouse; BioLegend) and stained
at 48C for 20 minutes in antibody diluent (PBS with 2% FBS)
with cell surface antibodies (Table). For intracellular staining,
fixation buffer (Cat. No. 420801; BioLegend) and intracellular
FIGURE 3. Co-MSCs have an antiangiogenic profile by protein expression. (A) Human angiogenesis array was used to profile pro- and
antiangiogenesis mediators in the Co-MSC secretome. It revealed it has high levels of antiangiogenic factors, whereas low levels of proangiogenic
factors. (B) The secretome from Co-MSCs contains high levels of sFLT-1 (1875 6 677 pg/mL); PEDF (4829 6 2342 pg/mL); TSG-6 (643.3 6 149.1
pg/mL); and low amount of VEGF-A (106.9 6103.3 pg/mL; n ¼ 5). The values shown are mean 6 SD (error bars).
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staining perm wash buffer (Cat. No. 421002; BioLegend) were
used according to manufacturer’s protocol. Flow cytometry
data was acquired on the BD LSR Fortessa (BD Pharmingen).
Data were analyzed using analytical software (FlowJo; FlowJo
LLC, Ashland, OR, USA).
Western Blot Analysis
Cells cultured on 100-mm dishes were rinsed twice with PBS
and harvested in SDS RIPA buffer (Sigma-Aldrich Corp.)
supplemented with protease/phosphatase inhibitors (Sigma-
Aldrich Corp.). After protein concentration measurement,
equal amounts of each sample were mixed with 2X Laemmli
buffer (Bio-Rad Laboratories, Hercules, CA, USA) and 5% beta-
mercaptoethanol (Sigma-Aldrich Corp.), denatured by heating
at 958C for 10 minutes, and subjected to electrophoresis on 4%
to 20% Tris-Glycine gels (Invitrogen, Grand Island, NY, USA).
The protein bands were transferred to polyvinylidene di-
fluoride membranes. The membranes were incubated in 5%
BSA in tris-buffered saline (TBS) for 1 hour followed by an
overnight incubation (48C) with primary antibodies at the
optimal concentration. The membranes were washed with TBS
with 0.03% Tween 20 and incubated with the horseradish
peroxidase–conjugated secondary antibody for 1 hour at room
temperature. Detection was performed with commercial
detection system (ECL Plus Western Blotting Detection System;
Amersham, Buckinghamshire, UK). Mouse Serpin F1/PEDF
antibody (AF1149) was purchased from R&D Systems.
Data Analysis and Statistical Comparisons
To obviate observer bias and to increase reproducibility, all the
animal surgeries were done by one of the authors who was
blinded to the treatment arms. Data collection and analyses
were done in a masked fashion to minimize inter- and
intraobserver bias. Eyes with infection were excluded from
the study. Corneal infection was defined as corneal edema,
hypopyon, and exudate within the first 7 days after the
procedure. Results are presented as the mean 6 SD of three
independent experiments. Normality of the data was tested
using D’Agostino & Pearson normality test. Based on normality
test, Mann-Whitney U-test or 2-sided student’s t-test was
performed to determine significance, which was set at P <
0.05. For more than two arms comparison, 1-way ANOVA with
Tukey’s post hoc correction was used. All statistics were
performed using statistical and spreadsheet software (Graph-
Pad Prism 7.0; GraphPad Software, Inc., La Jolla, CA, USA, and
Excel; Microsoft Corp., Redmond, WA, USA).
RESULTS
Co-MSC Secretome Is Antiangiogenic
Co-MSCs were successfully isolated from human and mouse
corneas and characterized to meet the minimal International
Society of Cell Therapy criteria for defining MSCs (Fig. 1).
Previous studies have demonstrated that the therapeutic effects
of MSCs are largely mediated through their secreted factors.20,21
We proceeded to test Co-MSC secretome using in vitro assays of
angiogenesis. The results indicated that Co-MSC secretome
significantly inhibits vascular sprouting and endothelial tube
formation compared to control media (Figs. 2A, 2B).
Co-MSCs Have an Antiangiogenic Profile by
Protein Expression
Human angiogenesis array was used to profile pro- and
antiangiogenesis mediators in the Co-MSC secretome. It
revealed it has high levels of antiangiogenic factors, whereas
low levels of proangiogenic factors (Fig. 3A). Based on the
results of proteome array and previous studies, we focused
specifically on sFLT-1 and PEDF (product of gene serine
proteases inhibitor F1; SERPINF1), two important soluble
mediators of corneal angiogenic privilege.11,22,23 Co-MSCs
from multiple donors consistently expressed and secreted
high levels of sFLT-1 and PEDF, whereas Co-MSCs secretome
from multiple donors contained low levels of VEGF-A. Co-
MSCs also secreted high levels of TNF-stimulated gene 6 (TSG
6), a well-known anti-inflammatory mediator of MSCs (Fig.
3B).
Co-MSCs Have Antiangiogenic Effects In Vivo
We tested Co-MSCs in an in vivo model of pathologic corneal
neovascularization. In this model, the entire corneal epitheli-
um is mechanically debrided that results in severe corneal
neovascularization. MSCs were embedded in a fibrin gel and
applied to the cornea immediately after the injury (Fig. 4A). In
vivo microscopy confirmed the presence of fluorescent-labeled
MSCs in the cornea 3 days after the procedure (Fig. 4B). The
results demonstrated that Co-MSCs could effectively prevent
corneal neovascularization (Fig. 4C).
Antiangiogenic Effects of Co-MSCs Depend on
Secreted sFLT-1 and PEDF
To investigate the role of sFLT-1 and PEDF in the antiangiogenic
effects of Co-MSCs, immunoprecipitation was used to remove
them from the secretome. Removing sFLT-1 or PEDF from Co-
MSC secretome resulted in a significantly increased tubule
formation in a HUVEC assay. The effects appeared to be
FIGURE 4. Co-MSCs inhibit pathologic corneal neovascularization in
vivo. (A) Schematic illustration shows the steps for debriding the
epithelium, MSC delivery using fibrin gel and temporarily closing the
lids. (B) In vivo microscopy confirmed the presence of fluorescent-
labeled MSCs in the cornea three days after the procedure. Scale bars:
200 lm. (C) The slit lamp photos and CD31 staining demonstrated
both Co-MSCs significantly prevented corneal neovascularization
compared to fibrin gel alone 14 days after injury. The values shown
are mean 6 SD (error bars). *P < 0.001. We used 1-way ANOVA and
then 2-sided t-test were used to compare the groups (n ¼ 5).
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additive; removing both factors resulted in a more significant
reduction in the antiangiogenic effects of Co-MSC secretome
(Fig. 5A). The efficiency of immunoprecipitation for PEDF and
sFLT1 was more than 95% as determined by ELISA (Fig. 5B).
Knocking down PEDF in Co-MSCs, using siRNA, likewise
decreased the antiangiogenic activity of its secretome in vitro
(Fig. 6). To examine the effect of PEDF in vivo, we isolated Co-
mMSCs from SERPINF1/ mice and compared them to wild-
FIGURE 6. Direct antiangiogenic properties of Co-MSCs are in part due to PEDF. Knocking down PEDF in Co-MSCs by siRNA obviates the
antiangiogenic effects of their secretome and increases tubule formation in a HUVEC assay (n¼4, 1-way ANOVA, and then 2-sided t-test were used to
compare the groups). *P < 0.001. (B) Knocking down PEDF by siRNA decreased PEDF protein by almost 90% compared to scrambled siRNA (n¼4,
2-sided t-test: *P < 0.0001). Boxes show the interquartile (25%–75%) range; whiskers encompass the range (minimum–maximum); and horizontal
lines represent the mean. Scale bars: 100 lm. SC, Scrambled.
FIGURE 5. Direct antiangiogenic properties of Co-MSCs depend on PEDF and sFLT-1. (A) Removing sFLT-1 and PEDF with neutralizing antibody
capturing and immunoprecipitation abrogated the antiangiogenic property of Co-MSC secretome in a HUVEC assay (n¼5 1-way ANOVA and then 2-
sided t-test were used to compare the groups). *P < 0.001. (B) The efficiency of immunoprecipitation for PEDF and sFLT1 was more than 95%
determined by ELISA (n¼5, 2-sided t-test: *P < 0.0001). Boxes show the interquartile (25%–75%) range; whiskers encompass the range (minimum–
maximum); and horizontal lines represent the mean. Scale bars: 100 lm. IP, immunoprecipitation.
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type Co-mMSCs using the injury model described earlier. The
results demonstrated that wild-type mouse corneas treated
with SERPINF1/ Co-mMSCs had significantly more neovas-
cularization compared to corneas treated with wild-type Co-
mMSCs (Fig. 7).
DISCUSSION
It is well accepted that the therapeutic effects of MSCs in many
disease processes are mediated largely through their immuno-
modulatory and anti-inflammatory properties.21,24–26 They
have been shown to modulate both innate and adaptive
immune mechanisms.27–29 Local tissue derived MSCs, which
share many features with other MSCs, can have additional
special attributes that may be potentially useful for certain
clinical applications.30–32 For instance, Co-MSCs were shown
to have antifibrotic effects and prevent the development of
corneal scarring after injury.1
While majority of studies have shown BM and adipose
derived MSCs are proangiogenic, there has been reports that
BM-MSCs can block corneal neovascularization.33–38 In partic-
ular, MSCs from different sources have been shown to secrete
several angiostatic factors, including thrombospondin 1; tissue
metalloproteinase inhibitor 1; pentraxin-3 (TSG-14); and
PEDF.37,39–47 In general, the mechanisms that have been
proposed for the antiangiogenic effects of MSCs are indirectly
based on their anti-inflammatory properties rather than direct
antiangiogenic effects.37 The current study provides the first
direct evidence that Co-MSCs have direct antiangiogenic
effects, through high secretion of antiangiogenic factors such
as sFLT-1 and PEDF and low secretion of angiogenic factors
including VEFG-A (Fig. 8). This finding has important
translational implications for corneal diseases that involve
neovascularization.
Soluble VEGF receptor (VEGFR-l, sFLT-1) predominantly
derives from alternative splicing,48 but possibly also from
proteolytic cleavage of full-length VEGFR-1.49 The molecular
mechanisms of the purported antiangiogenic effects of sFLT-1
are believed to include: sequestration of VEGF ligands, much
like VEGFR-1 does, and effectively reducing VEGF-mediated
activation of proangiogenic receptors,11,50 and heterodimeriza-
tion with full-length VEGFR monomers to render the receptor
dimer inactive, because sFLT-1 lacks the intracellular tyrosine
kinase domain needed to transphosphorylate its full-length
partner.51–53 Moreover, several biologic functions of sFLT-1
have been deduced from its capacity to neutralize VEGF:
antiangiogenesis, by dampening angiogenic VEGF-VEGFR-2
signaling54,55; anti-edema, by interfering with VEGF-mediated
vascular permeability through VEGFR-1 or VEGFR-255,56; and
anti-inflammation, by attenuating VEGF-VEGFR-1-dependent
monocyte and macrophage activation and migration.57
It is well accepted that sFLT-1 is an important factor in
corneal avascularity.58–61 It is produced mainly by corneal
epithelial cells.11 In our in vivo studies, the contribution of
epithelial secreted sFLT-1 was not specifically studied; howev-
er, our in vitro results confirm that Co-MSCs secrete sFLT-1 at
high enough level to inhibit angiogenesis.
PEDF is a 50 kD multifunctional secreted glycoprotein.62
Many studies have substantiated its potent antiangiogenic
activity and the opposing actions of PEDF and VEGF in
controlling quiescence and permeability of the vasculature.62–65
PEDF has several different mechanisms including competitive
binding to the VEGFR-2,66 c-secretase-mediated cleavage, and
translocation of a fragment of the VEGFR-1,49,65 as well as
alteration of the phosphorylation status of VEGFR-l.49,65 The
importance of PEDF in corneal avascularity has been well
documented.67–74
This study further highlights the distinct characteristics as
well as the translational potential of local tissue–derived MSCs.
While MSCs from various tissues share the minimal Interna-
tional Society of Cell Therapy criteria for defining MSCs, they
often have differences in functional properties based on their
tissue of origin.75,76 In the case of Co-MSCs, while many of
their anti-inflammatory effects may be potentially shared by
other MSC types based on their common repertoire of anti-
inflammatory factors, their direct antiangiogenic effects may be
a more distinctive feature. Given the feasibility of generating
clinical grade Co-MSCs from human cadaveric corneas, they
provide an attractive cell source for developing regenerative
FIGURE 7. PEDF plays a key role on the antiangiogenic properties of
Co-MSCs in vivo. (A) Western blot shows Co-MSCs isolated from
SERPINF1/ mice do not express PEDF. (B) Co-MSCs isolated from
SERPINF1/mice had lower antiangiogenic effects, compared to wild-
type (SERPINF1þ/þ) Co-MSCs, when placed in fibrin gels after corneal
epithelial injury in wild-type mice (same model as in Fig. 4A; n¼ 5, 2-
sided t-test: *P ¼ 0.0001). Scale bars: 500 lm. The values shown are
mean 6 SD (error bars). Co-mMSCSF1, corneal mouse MSCSERPINF1;
NV, neovascularization.
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FIGURE 8. Schematic illustration summarizes the mechanisms by which Co-MSCs confer their antiangiogenic properties. (A) After corneal epithelial
injury, DAMPS, chemokines, and cytokines released by the injured and resident cells directly induce angiogenesis while also recruiting inflammatory
cells that further promote angiogenesis. The net effect is shifting the antiangiogenic balance of the cornea toward angiogenesis. (B) Co-MSCs
applied to the cornea after injury modulate neovascularization directly through the secretion of antiangiogenic factors including PEDF and sFLT-1
and indirectly by suppressing inflammation via TSG6 and other anti-inflammatory factors. DAMP, damage-associated molecular pattern.
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antiangiogenic and immunomodulatory therapies for the
cornea and potentially other tissues.
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